{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122839","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.912385+00:00","generated_at":"2026-05-30T03:34:11.024065+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Corbus Q3 net loss $13.8M; CRB-701 dose escalation complete; cash $159.4M","bullets":["Net loss of $13.8M ($1.15/diluted share) vs $10.1M ($2.27) in Q3 2023; operating expenses up $6.0M to $15.5M.","Cash, cash equivalents and investments $159.4M; expects to fund operations through Q3 2027.","Raised $35.6M net proceeds via ATM program in Q3 by issuing 663,730 shares.","Completed enrollment in CRB-701 dose escalation part of Phase 1; first data expected in Q1 2025.","Final $11.8M loan payment made; loan fully paid off."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122839","json":"https://secwatch.observer/filing/0000950170-24-122839.json","markdown":"https://secwatch.observer/filing/0000950170-24-122839.md","text":"https://secwatch.observer/filing/0000950170-24-122839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024122839/0000950170-24-122839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024122839/crbp-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:34:11.024065+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}